Therapeutics/Diagnostics News

WASHINGTON — Surveillance colonoscopy after polyp removal was associated with a 77% relative reduction in risk for colorectal cancer, although more research is needed to determine its effect on mortality risk, according to study results.

WASHINGTON — The Primary Obesity Surgery Endoluminal 2.0 procedure is a “safe, effective and durable option” for weight loss and improvement in obesity-related conditions, according to a presenter.

WASHINGTON — Seladelpar use led to “rapid, marked and sustained improvement” in markers of cholestasis and liver injury among patients with primary biliary cholangitis, according to interim results of the ongoing, phase 3 ASSURE study.

In a Healio exclusive, Ari Grinspan, MD, predicted that while microbiota therapeutics are currently “not ready for prime time,” they will eventually become part of the treatment strategy for patients with inflammatory bowel disease.

The FDA has declined to approve Dynavax’s supplemental biologics license application for the expanded use of its four-dose hepatitis B vaccine regimen in adult patients on hemodialysis, according to a manufacturer’s press release.

The FDA has granted orphan drug designation to a microbiome-modifying biologic to treat Angelman syndrome, according to the manufacturer.

Oral samples taken from patients with gastric cancer and premalignant gastric conditions exhibited “stark differences” in bacterial composition compared with controls, suggesting that oral bacteria could serve as a biomarker.

A delayed diagnosis of appendicitis was associated with an increase in hospital care costs in a cohort of adults who underwent appendectomy, particularly among non-Hispanic Black patients, according to data in JAMA Network Open.

A dual-ring plastic wound protecter reduced the risk for surgical site infection by 46.81% compared with conventional surgical gauze during open abdominal gastrointestinal surgery, according to study results.

Approximately two-thirds of patients with Crohn’s disease who initially responded to anti-tumor necrosis factor therapy lost response by 3 years, with researchers suggesting that higher drug concentrations at induction may improve outcomes.